NOVAVAX INC Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- NOVAVAX INC stock issued during period, value, new issues for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- NOVAVAX INC stock issued during period, value, new issues for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- NOVAVAX INC stock issued during period, value, new issues for the quarter ending 2024-06-30 was $256.41M, a 277.23% increase year-over-year.
- NOVAVAX INC stock issued during period, value, new issues for the quarter ending 2023-12-31 was $110.11M, a 57.65% increase year-over-year.
- NOVAVAX INC stock issued during period, value, new issues for fiscal 2024 was $256.41M, a 30.15% decline from fiscal 2023.
- NOVAVAX INC stock issued during period, value, new issues for fiscal 2023 was $367.11M, a 47.30% increase from fiscal 2022.
- NOVAVAX INC stock issued during period, value, new issues for fiscal 2022 was $249.23M, a 55.88% decline from fiscal 2021.
- NOVAVAX INC stock issued during period, value, new issues for fiscal 2021 was $564.86M, a 35.73% decline from fiscal 2020.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $256.41M 10-K · filed 2026-02-26 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | |
| 2024-06-30 | $256.41M 10-Q · filed 2025-08-06 | |
| 2023-12-31 | $110.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $367.11M 10-K · filed 2026-02-26 |
| 2023-09-30 | $189.02M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $67.97M 10-Q · filed 2024-08-08 | |
| 2022-12-31 | $69.84M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $249.23M 10-K · filed 2025-02-27 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $179.38M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $179.38M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $179.38M 10-Q · filed 2023-05-09 | $179.38M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $564.86M 10-K · filed 2024-02-28 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $992.76M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $1.05B derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $564.86M 10-Q · filed 2022-05-10 | $1.26B derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $427.90M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $878.85M 10-K · filed 2023-02-28 |
| 2020-09-30 | $57.19M 10-Q · filed 2021-11-05 | $481.01M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $207.84M 10-Q · filed 2021-08-05 | $436.41M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $185.92M 10-Q · filed 2021-05-10 | $228.57M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $30.06M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $97.89M 10-K · filed 2022-03-01 |
| 2019-09-30 | $12.59M 10-Q · filed 2020-11-10 | $71.40M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $3.00K 10-Q · filed 2020-08-10 | $58.82M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $55.24M 10-Q · filed 2020-05-11 | $112.70M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $3.57M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $100.06M 10-K · filed 2021-03-01 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | |
| 2018-06-30 | $53.89M 10-Q · filed 2019-08-07 | |
| 2018-03-31 | $42.60M 10-Q · filed 2019-05-02 | |
| 2017-12-31 | $63.42M 10-K · filed 2020-03-11 | |
| 2015-12-31 | $204.28M 10-K · filed 2018-03-14 | |
| 2014-12-31 | $107.89M 10-K · filed 2017-02-27 | |
| 2013-12-31 | $136.59M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $170.59M 10-K · filed 2016-02-29 |
| 2012-12-31 | $53.16M 10-K · filed 2015-02-27 | |
| 2011-12-31 | $11.83M 10-K · filed 2014-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |